SEC Filing Analysis: Vivani Medical, Inc. (VANI)

Executive Summary

• Trading Significance: Medium
• Key Takeaway: Vivani Medical filed a Form 424B5 prospectus supplement registering the resale of up to 3,947,368 common shares issuable upon exercise of outstanding warrants held by Sabby Volatility Warrant Master Fund.
• Market Impact: Potential supply overhang of ~4.58% of shares outstanding, tempered by the warrants currently being significantly out of the money ($3.80 exercise price vs. $1.23 recent trading price).

Company Information

Field	Value
Company	Vivani Medical, Inc.
Ticker Symbol	VANI
CIK	0001266806
Industry	Electromedical & Electrotherapeutic Apparatus

Insider / Selling Holder Information

Field	Value
Name	Sabby Volatility Warrant Master Fund, Ltd.
CIK	Not applicable
Title/Position	Institutional Investor / Warrant Holder
Relationship	Selling Securityholder

Transaction Details

Field	Value
Form Type	424B5 (Prospectus Supplement)
Filing Date	September 25, 2026
Security Type	Common Stock (issuable upon warrant exercise)
Shares Involved	3,947,368
Exercise Price	$3.80 per share
Recent Share Price	$1.23 (as of Sept 24, 2026)
Potential Exercise Proceeds	Up to $15,000,000 (if exercised for cash)
Resale Market Value	~$4,855,263 (at current $1.23 price)

Financial Impact Assessment

Transaction Materiality

Metric	Value
Resale Value (at Market)	$4,855,263
% of Market Cap ($110M)	4.41%
Shares Registered	3,947,368
% of Shares Outstanding (86.24M basic)	4.58%
Pre-Offering Outstanding Shares	90,203,356 (as reported in filing)
Post-Exercise Outstanding Shares	Up to 94,150,724
Materiality Assessment	Significant dilution/overhang capacity

Impact Evaluation

• Market Cap Context: For a micro-cap biopharmaceutical company with a $110M market cap, registration of 4.58% of outstanding shares represents a notable overhang.
• Warrant Dynamics: The warrants carry an exercise price of $3.80, expiring March 1, 2027. Because shares traded at $1.23 as of September 24, 2026, the warrants are deeply out of the money, precluding immediate cash exercise or liquidation in normal market conditions.
• Dilution Impact: Full exercise would dilute existing stockholders by ~4.19% of post-exercise capital, while potentially injecting up to $15M in cash to the issuer if exercised for cash, although cashless exercise provisions may also apply under specific conditions.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: This prospectus fulfills existing contractual registration obligations under the March 1, 2024 Securities Purchase Agreement. Given the $3.80 exercise barrier relative to the current $1.23 market price, immediate selling pressure is unlikely.

Volume & Sentiment

• Expected Volume Impact: Neutral in the short term; may create overhead resistance if the stock rallies toward the $3.80 warrant strike level.
• Sentiment Indicator: Neutral

Additional Context

• Origin of Securities: The underlying warrants were issued in March 2024 concurrently with a common stock offering under a prior shelf registration statement.
• Ownership Restrictions: Exercises are subject to a 4.99% beneficial ownership limitation (expandable to 9.99% upon 61 days notice), preventing rapid accumulation above standard micro-cap thresholds.
• Company Operations: Vivani is progressing its preclinical/clinical NanoPortal subdermal implant platform, including GLP-1 programs NPM-139 and NPM-133.